Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 3/20 | 0.30 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | GRK2 | P25098 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15672743 | 0.82 | TLR8 (0.53) | TLR9TLR8TLR7FFAR1MRGPRX4 | |
| SCHEMBL14771917 | 0.80 | TLR9 (0.48) | TLR9TLR8TLR7KDM1AHTT | |
| SCHEMBL13165292 | 0.78 | TLR9 (0.47) | TLR9TLR8TLR7FFAR1KDM1A | |
| SCHEMBL14293951 | 0.75 | MRGPRX4 (0.37) | FFAR1MRGPRX4KDM1APDE2ASMN1; SMN2 | |
| SCHEMBL13498029 | 0.75 | KDM4E (0.46) | FFAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8228423 | 0.73 | KDM1A (0.47) | FFAR1MRGPRX4KDM1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14293948 | 0.70 | MRGPRX4 (0.38) | FFAR1MRGPRX4KDM1APDE2ASMN1; SMN2 | |
| SCHEMBL9945951 | 0.70 | HTT (0.41) | FFAR1MRGPRX4SMN1; SMN2HTTGAA | |
| SCHEMBL20232153 | 0.70 | L3MBTL1 (0.41) | FFAR1MRGPRX4PDE2ASMN1; SMN2HTT | |
| SCHEMBL11951596 | 0.70 | ACACB (0.45) | TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | TLR9 3784/4885TLR8 3936/4885TLR7 3579/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | TLR9 3784/4885TLR8 3936/4885TLR7 3579/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | TLR9 1606/4885TLR8 1951/4885TLR7 1734/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TLR9 4859/4885TLR8 4754/4885TLR7 4244/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TLR9 4859/4885TLR8 4754/4885TLR7 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.